Fig. 5From: Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 dataThe predicted probabilities of experiencing a DLT and corresponding 95 % prediction intervals for the conservative prior skeleton approach in the extended CRM method after the inclusion of the first five AZD3514 patientsBack to article page